The trial behind the analysis, known as the Prostate Cancer Active Lifestyle Study or PALS, enrolled 100 men between 2016 and 2020 who were on active surveillance for prostate cancer and carried excess weight. Active surveillance has become the dominant management strategy for low-risk disease in the United States, sparing men the urinary, bowel, and sexual side effects that follow surgery or radiation. But surveillance carries its own psychological burden, and many of these men are also contending with the health consequences of overweight and obesity. The researchers, led by a team at the University of Washington School of Medicine and Fred Hutchinson Cancer Center in Seattle, randomly assigned participants to either an intensive six-month intervention targeting seven percent weight loss through dietary change and exercise, or to a control arm that received the US Dietary and Physical Activity Guidelines.

On the primary metabolic goal, the intervention worked as designed. Men in the lifestyle arm lost an average of 7.1 percent of their body weight, a clinically meaningful reduction that meets widely accepted benchmarks for obesity management, while men in the control group lost only 1.8 percent. That contrast is important because it establishes that the trial had sufficient behavioral potency: the intervention genuinely changed what it set out to change. Any failure to move quality-of-life scores therefore cannot be dismissed as a failure of the program to engage participants. The men dieted, exercised, and lost weight; the question was whether their day-to-day wellbeing followed.

To answer that question rigorously, the investigators deployed four validated instruments at baseline and at the end of the intervention. The EQ-5D-5L captured general health-related quality of life across mobility, self-care, usual activities, pain, and anxiety. The International Prostate Symptom Score, or IPSS, quantified urinary symptoms and their impact. The EPIC-26, an abbreviated version of the Expanded Prostate Cancer Index Composite, measured the domains most specific to prostate cancer survivors: urinary, bowel, and sexual function and the bother each one causes. Finally, the Memorial Anxiety Scale for Prostate Cancer, or MAX-PC, assessed cancer-specific anxiety, including fear of progression, a known driver of distress among men on surveillance. Linear regression models and two-sided t-tests compared mean changes between the arms.

The headline result was null across the board. There were no statistically significant differences between the intervention and control groups in general quality of life, urinary quality of life, prostate cancer-related quality of life, or prostate cancer-specific anxiety. In other words, losing more than seven percent of body weight over six months did not make men on active surveillance feel meaningfully better than men who received only standard guidelines. For a field that has invested heavily in exercise and dietary trials for this population, the result is a genuine counterweight to optimism. Previous studies of exercise alone, including randomized trials of walking programs and high-intensity interval training in men on surveillance, have produced mixed signals, and a large dietary trial known as the Men’s Eating and Living Study likewise found no quality-of-life benefit from a high-vegetable diet.

Yet the story does not end with the null result. In exploratory subgroup analyses, the researchers stratified participants by baseline scores on EPIC-26 domains, using cut-points that correlate with clinical assessments of function. Here, targeted benefits emerged. Men who started with poor bowel function improved by an average of 12 points on the EPIC-26 bowel domain, with a 95 percent confidence interval of 0.1 to 24.0. Men with low sexual bother at baseline improved by 22 points, with a confidence interval of 4.2 to 39.0, and men who began with good sexual function improved by 19 points, with a confidence interval of 4.4 to 34.0. On an instrument where the minimally important difference is typically in the range of a handful of points, changes of this magnitude are clinically significant, not merely statistical noise.

Why might weight loss help some subgroups and not others? The biology offers plausible threads. Obesity is strongly associated with functional gastrointestinal complaints, and dietary change, particularly shifts toward higher fiber intake, has been shown in conditions such as ulcerative colitis to reduce inflammatory markers and improve quality of life. Men with poor bowel function at baseline may therefore have had the most physiological room to benefit from a dietary overhaul. Similarly, randomized evidence in obese men without cancer has shown that lifestyle change can improve erectile function, likely through improved vascular health, which could explain gains among men with preserved sexual function who still reported bother. The subgroup findings are exploratory and come with wide confidence intervals, but they suggest that a one-size-fits-all quality-of-life endpoint may be masking benefits concentrated in identifiable patient profiles.

The null overall result also says something about the population itself. Men choosing active surveillance are, by selection, often healthier and less symptomatic than men undergoing treatment, and population norms for instruments like the EQ-5D-5L show that many men in this cohort may already be functioning near baseline levels of general wellbeing. When there is little room to improve, even a successful intervention cannot demonstrate gains. Anxiety scores, too, may be buffered by the reassurance of regular monitoring rather than responsive to metabolic change. The trial’s six-month horizon is another constraint: quality-of-life effects of sustained weight loss and fitness gains may take longer to materialize, or may depend on maintaining the weight loss beyond the intervention period.

The authors are careful about what their data do and do not support. The conclusion is not that diet and exercise are useless for men on active surveillance, but that they should not be prescribed primarily as quality-of-life therapy for this population as a whole. The broader rationale for lifestyle intervention remains intact and arguably stronger: weight management reduces cardiovascular risk, and cardiovascular disease is a leading cause of death among men with localized, low-risk prostate cancer who are far more likely to die with their cancer than of it. Exercise guidelines for cancer survivors, established by an international multidisciplinary roundtable, rest on evidence for fitness, function, and long-term health, not on guaranteed short-term mood or symptom improvements.

For clinicians counseling the growing cohort of men on surveillance, the practical message is one of precision rather than abandonment. A structured six-month program with a seven percent weight-loss target is achievable and delivered real weight loss in this trial. It may be worth prioritizing for patients who present with bowel symptoms or sexual bother, where the exploratory signals were strongest, while being honest with others that the intervention is unlikely to change how they feel day to day in the near term. Larger trials with longer follow-up, prespecified subgroup hypotheses, and maintenance-phase assessments will be needed to confirm whether targeted lifestyle prescriptions can convert physiological gains into felt improvements. For now, the study stands as a reminder that in cancer care, as in medicine generally, the distance between changing the body and changing the experience of living in it is real, measurable, and worth mapping with the same rigor applied to tumors themselves.

Subject of Research: Effects of a diet and exercise intervention on quality of life in overweight prostate cancer patients on active surveillance

Article Title: Impact of a dietary and exercise intervention on health-related quality of life of prostate cancer patients on active surveillance with overweight/obesity: a secondary analysis of a randomized controlled trial

Article References: Impact of a dietary and exercise intervention on health-related quality of life of prostate cancer patients on active surveillance with overweight/obesity: a secondary analysis of a randomized controlled trial. (n.d.). https://doi.org/10.1007/s00520-026-11298-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11298-2

Keywords: prostate cancer, active surveillance, quality of life, diet, exercise, weight loss, obesity, randomized controlled trial, EPIC-26, patient-reported outcomes, lifestyle intervention, supportive care